Boston Scientific (BSX) said Monday it has agreed to buy medical device company Intera Oncology for an undisclosed sum.

The deal, which will likely close in H1 2025, is expected to have an immaterial effect on adjusted earnings in 2025 and be more dilutive on a GAAP basis owing to acquisition-related net charges and amortization expense, the company said.